来自 Propecia 诉讼的未密封文件现在存放在 PFS 基金会网站上

June 28, 2021

Dear Friends:

The PFS Foundation has launched a new section of its website to house documents from the US Propecia litigation unsealed by court order earlier this year.

Part A of our Propecia Litigation Library (Paper Trail), contains 479 pages of such documents, along with 125 pages of related content, including Merck’s FDA filing for the addition of depression to the Propecia label.

Part B (Media Pursuit) contains 17 media reports, published in the US and abroad over three decades, that track the Propecia narrative from FDA approval of the drug in 1997 to revelations from the unsealed documents earlier this year.

In 1997, for example, The New York Times noted, “Critics…complain that no long-term studies have been conducted on” Propecia (A Pill for Male Pattern Baldness Wins Approval From the FDA).

Twenty-four years later, in February 2021, Reuters wrote, “Since…2011…the FDA has received more than 700 reports of suicide and suicidal thoughts among people taking Propecia or generic versions… Those included at least 100 deaths” (Exclusive: Merck Anti-baldness Drug Propecia Has Long Trail of Suicide Reports, Records Show).

The unsealing effort got under way in September 2019 when Reuters published an investigative report that uncovered testimony by former Merck executives suggesting that the pharmaceutical giant downplayed the drug’s side effects during clinical trials.

A day after that story broke, the news agency filed a motion in US Federal Court to unseal documents filed in the Propecia litigation, noting, “This is a case of tremendous importance that has been sealed without on-the-record findings explaining that sealing. The First Amendment precludes such an outcome.”

Sixteen months later, on January 25, US Magistrate Judge Peggy Kuo approved Reuters’ motion, clearing the way to make documents in the Propecia litigation public.

In her decision, Kuo noted that Merck’s arguments for keeping those documents under wraps “are so weak that they would not overcome even a low presumption of access under the common law.”

Anyone living in the US who suffers from PFS should report his/her symptoms to the US Food and Drug Administration. Anyone living outside the US who suffers from PFS should report his/her symptoms to the US Food and Drug Administration as well as to his/her national drug-regulatory agency, as directed on our Report Your Side Effects page.

If you or a loved one are suffering from PFS, and feeling depressed or unstable, do not hesitate to contact the PFS Foundation via our Patient Support hotline: social@pfsfoundation.org.

Thank you.

Related News

Young Men Using Finasteride for Alopecia May Be More Suicide-Prone than the General Population, Says New Pharmacovigilance Research

Gut Microbiota Population is Altered in PFS Patients, New Research Demonstrates (Sept. 28, 2020)

Penile Vascular Abnormalities Found in Majority of PFS Patients in Baylor College of Medicine Study (April 28, 2020)

Young Men Who Use Finasteride for Hair Loss ‘Are at Risk for Suicide if They Develop Persistent Sexual Adverse Effects and Insomnia,’ Says New Research (Feb. 20, 2020)

Epigenetic Modifications Do Occur in PFS Patients, New Research Demonstrates (July 20, 2019)

Evidence of Increased ED Rates in Finasteride Patients Is ‘More Compelling’ than Evidence Against, Says New Paper in JAAD (June 5, 2019)

Finasteride ‘Causes Several Alterations’ in the Section of the Brain Responsible for Processing Long-term Memory and Emotional Responses, New Animal-model Study Demonstrates (Oct. 1, 2018)

Common Pathways Between PFS and Post-SSRI Sexual Dysfunction Could Be Useful in Designing Therapeutic Strategies for Both, Says New University of Milano Study (April 30, 2018)

Peripheral Nervous System Involved in PFS Patients with Severe ED, New Study Demonstrates (April 18, 2017)

Feinberg School of Medicine Epidemiology Study Suggests Tens of Thousands of PFS Cases in Young Men TakingFinasteride for Hair Loss (March 9, 2017)

‘Underlying Neurobiological Abnormalities’ Exist in Finasteride Users with Persistent Sexual Dysfunction, Suggests Clinical Study (Sept. 29, 2016)